Peptide Insider

Petrelintide Side Effects: What the Trials Actually Measured

Petrelintide side effects — what the trials actually measured

Written by Marcus Reinhardt · Lead Analyst, Peptide Insider · LinkedIn

Evidence-first peptide coverage — every claim on this page is linked to its primary source and reviewed against our editorial policy

Citations verified against PubMed · Published: 2026-09-04 · Last updated: 2026-09-07

Petrelintide side effects have been measured in exactly two published human trials — a single-ascending-dose study and a multiple-ascending-dose study, both randomized, double-blind, and placebo-controlled, reported together in 2026. The headline is unusually quiet for an amylin-class compound: nausea in 16.7%–33.3% of participants on drug versus 16.7% on placebo, no serious or severe adverse events, one discontinuation. The catch this page will not let go of: these are phase 1 cohorts, small enough that the abstract doesn’t report a headcount, and phase 1 tolerability has a long history of reading better than phase 2 doses later reveal. Here are the numbers as published, and where they stop applying to a research vial.

Quick Answer: The Most Common Petrelintide Side Effects

In both phase 1 trials, the most common adverse events were gastrointestinal, and most were mild. Nausea, the most common GI event, occurred in 16.7%–33.3% of participants receiving petrelintide versus 16.7% on placebo in the 16-week part of the multiple-dose trial. Diarrhea was rare, vomiting was reported by one participant — the trial’s single GI discontinuation — and there were no serious or severe treatment-emergent adverse events in either study. The caveat that runs through this page: these are phase 1 cohorts, and the abstract does not say how many people were in them. We also searched Reddit for self-reports and found none; that search is summarized further down.

★The Documented Experience of Petrelintide’s Phase 1 Trial Participants

The most complete “user experience” of petrelintide that exists belongs to the people who took it under observation — and the abstract does not report how many that was, so neither will we. What it does report: once-weekly injections, body weight down by as much as 8.6%, and side effects that were mostly stomach-related and mostly mild.

How tolerable did participants find it? No serious or severe treatment-emergent adverse events in either trial, and exactly one person stopped because of GI effects. The placebo group reported nausea too — 16.7%, the same figure as the lowest petrelintide rate. The authors’ verdict: petrelintide “appeared safe” with “a low incidence of GI TEAEs.”

What that came with: screening, monitoring, pharmaceutical-grade product from Zealand Pharma, and clinician-managed escalation — none of which ships with a research vial.

Compiled from the published trials (PMID 42017294, PMID 41217931) — not from testimonials. When we publish an individual account here, it will be a real person, named with permission.

Research peptide vial

Looking for Lab-Tested Peptides?

Our top-rated vendor publishes batch COAs and third-party testing on every compound — get up to 30% off your first order.

Shop Amino Club →

Affiliate link — it doesn’t change what we report. All compounds sold strictly for non-human research use. Read our full Amino Club review.

In This Guide

What Is Petrelintide?

Petrelintide (Zealand Pharma’s ZP8396) is a long-acting analogue of human amylin — the pancreatic satiety hormone released after eating — engineered for once-weekly subcutaneous injection and, unusually, for chemical stability at about neutral pH (PMID 41217931). That detail is the design brief: an analogue stable enough to be co-formulated with marketed weight-loss drugs. In humans it reduced body weight by up to 8.6% after 16 weeks (PMID 42017294) — a phase 1 figure, and the entire evidence base behind every research-market listing you will see. It is not an approved drug anywhere as of this writing; everything sold under this name outside a trial is research-market material.

How It Works — and Why the Design Bet Was Chemistry, Not Selectivity

Amylin is a physiological satiety signal released after nutrient intake (PMID 41217931); its analogues slow gastric emptying and act on satiety circuits, and their side effects are that mechanism turned up too far. Where Lilly’s eloralintide bet on receptor selectivity to soften that, Zealand stayed close to human amylin and solved the chemistry instead, optimizing stability while retaining in vitro and in vivo potency. The human pharmacokinetic result: slow absorption, a half-life of roughly 10 days, and steady-state dose proportionality (PMID 42017294).

KEY TAKEAWAY

Petrelintide’s design bet is pharmacokinetic and chemical rather than receptor-selective: a ~10-day half-life, slow absorption, and neutral-pH stability built for co-formulation. The phase 1 GI numbers are low. So is the number of people they were measured in — and the abstract doesn’t tell you what that number was.

The Trial Numbers That Matter

Two human datasets exist, published as one paper. The single-ascending-dose (SAD) trial tested subcutaneous petrelintide at 0.04–2.4 mg plus a 0.35 mg intravenous dose in normal-weight or overweight adults. The multiple-ascending-dose (MAD) trial had two parts: part 1 gave 6 once-weekly subcutaneous doses of 0.6 or 1.2 mg to normal-weight or overweight adults; part 2 gave 16 once-weekly doses, escalated every 2 weeks to target doses of 2.4, 4.8, or 9.0 mg, to adults with overweight or obesity. Both were randomized, placebo-controlled, and double-blind (PMID 42017294). What the abstract does not give: total enrollment, per-cohort headcounts, or per-dose adverse-event rates. The second citation, the J Med Chem development paper (PMID 41217931), is chemistry with no human safety numbers. That is the entire published human evidence base: two phase 1 trials of unreported size, sponsored and co-authored by the manufacturer.

Gastrointestinal Side Effects: The Real Rates

The numbers, exactly as reported: in MAD part 2, nausea occurred in 16.7%–33.3% of participants receiving petrelintide versus 16.7% for placebo. GI disorders were the most common adverse-event category in both trials, and most were mild. Diarrhea was rare — no rate is given — and vomiting was experienced by only one participant, the trial’s only GI discontinuation (PMID 42017294). Two readings matter. First, the abstract reports a range across cohorts, not per-dose values, so we cannot tell you which target dose — 2.4, 4.8, or 9.0 mg — produced the 33.3%. Second, percentages to one decimal place in a phase 1 cohort are the signature of small groups, where one participant moves the number by a large step; the abstract doesn’t give cohort sizes, so we won’t guess them.

PERSONAL OBSERVATION — PI EDITORIAL

Reading this abstract beside the amylin-class trials we’ve already covered, what struck us was how much work the phrase “in MAD part 2” is doing. It tells you the nausea range comes from the longest-exposure, highest-target-dose part of the program — the part most likely to show GI cost — and it still topped out at one in three, against one in six on placebo. But “low incidence of GI TEAEs” at this stage is a hypothesis about phase 2, not a result from it. Every amylin and GLP-1 compound we track looked gentler in its first-in-human paper than in its dose-ranging one.

The Placebo Floor: When the Lowest Petrelintide Rate Matched Placebo Exactly

The most distinctive figure in the petrelintide data is two identical numbers: the lowest nausea rate among petrelintide cohorts in MAD part 2 was 16.7%, and the placebo rate was 16.7% (PMID 42017294). Read literally, at least one active-drug cohort had zero attributable nausea in this sample — not a pattern we are used to seeing at the bottom of an amylin-class dose table. Now the counterweight. Placebo participants get weekly needles and the expectation of nausea too, which is why one in six reported it — and in a cohort small enough that the abstract declines to state its size, the gap between 16.7% and 33.3% may be a single person’s stomach. The placebo floor is a real, published data point. It is also the most fragile number on this page.

Injection-Site Reactions

Here is what the published abstract does not report: injection-site reaction rates. Administration-site events are not named among the most common adverse events in either trial (PMID 42017294), which tells you they weren’t a leading category and nothing more precise. It is a once-weekly subcutaneous injection, and the standard handling picture applies.

PRACTICAL NOTES — STANDARD SUBCUTANEOUS HANDLING

  • Reconstituted solutions brought to room temperature before use are standard practice in clinical settings
  • Site rotation (abdomen, thigh, upper arm) is how trial protocols manage repeated weekly injections
  • Sterile technique — clean site, single-use needles — is non-negotiable in any protocol, trial or lab
  • Our bacteriostatic water guide covers reconstitution handling in detail

Beyond the Gut: What Else the Trials Recorded

The abstract’s non-GI safety content is short: petrelintide was “well tolerated, with no serious or severe treatment-emergent adverse events” in either trial (PMID 42017294). No other adverse-event category — headache, fatigue, dizziness, heart rate — is named; only the full paper can say whether they were infrequent or merely unlisted. What it does document is pharmacokinetics: slow absorption, a half-life of about 10 days, dose proportionality at steady state — an exposure curve without weekly peaks. Cardiovascular outcomes appear nowhere in the published record, and we won’t convert that silence into reassurance. One context note: the trials were sponsored by Zealand Pharma, whose employees and shareholders are among the authors — normal for phase 1 work, and a reason to wait for independent replication.

What Users Report: Self-Reported Effects From Reddit

The two phase 1 trials above are the only human record of petrelintide, and Reddit adds nothing to it. We searched Reddit on September 5, 2026, found 11 relevant posts, and read the comment threads of two, dated 2025 and 2026, across r/Eloralintide and r/cagrilintide. Everything below is paraphrased and linked, uses no usernames, and describes products nobody verified. Petrelintide exists only inside Zealand Pharma’s trials, and nobody in either thread describes taking it.

What Reddit holds is news and class comparison, not experience. The newer thread flags a phase 3 start planned for late 2026; one commenter reads its stability chemistry as a design for co-formulation with a GLP-1, and another is waiting for a different company’s amylin trial (r/Eloralintide). The older thread asks why cagrilintide is the only amylin agonist anyone can buy while eloralintide and petrelintide are not available (r/cagrilintide).

The one experience account here cannot be attributed to petrelintide. A commenter in that thread describes being randomized to the top dose of an amylin analog in a trial, losing around sixty pounds, with fatigue for the first few weeks and constipation throughout. The comment naming the compound was not captured, so we do not count it.

The absence of reports has a practical implication. A vial labelled petrelintide arrives with no user record behind it: nobody can say whether it suppresses appetite or what it does at any dose, so an identity test is the only check that exists.

HOW TO READ SELF-REPORTS

The trials report mild, mostly gastrointestinal events and one discontinuation in cohorts of unreported size. Reddit adds nothing, because nobody outside a trial describes taking petrelintide; there is no anecdotal frequency to compare and no causation to argue. The nearest self-reports concern cagrilintide, a different molecule.

When Side Effects Happen — and When They Fade

No published petrelintide data supports a week-by-week side-effect calendar, and anyone offering one has invented it. What the design does tell you: MAD part 2 escalated doses every 2 weeks toward the 2.4, 4.8, and 9.0 mg targets over 16 weekly doses (PMID 42017294) — the standard recognition that GI effects concentrate around dose starts and increases. The abstract does not say when the one GI discontinuation occurred or whether nausea faded with continued dosing — questions a phase 1 of this size can’t answer, and the phase 2 will.

Long-Term Safety: What 16 Weeks Can and Can’t Tell You

The longest published petrelintide exposure is 16 once-weekly doses — the MAD part 2 duration — with the authors’ verdict that the compound “appeared safe” and produced “clinically relevant weight loss” of up to 8.6% (PMID 42017294). That is a reassuring first 16 weeks. It is also the entire horizon: no longer-term petrelintide safety data exists, because none can yet, and phase 2 results have not appeared in the peer-reviewed record. Anyone describing its one-year profile is forecasting, not reporting.

Who the Trials Enrolled — and What the Abstract Leaves Out

Trial safety numbers describe trial populations. The SAD trial and MAD part 1 enrolled normal-weight or overweight adults, while MAD part 2, the source of every nausea figure on this page, enrolled adults with overweight or obesity (PMID 42017294). That is all the abstract says: no age range, BMI thresholds, comorbidity exclusions, diabetes status, or headcount. What can be said is this: every rate here was generated in screened, monitored people, under a protocol that could stop a dose the moment a stomach objected — a boundary no research buyer replicates.

Managing and Minimizing Side Effects: What the Trials Did

The trials’ side-effect management was structural. MAD part 1 held doses fixed at 0.6 or 1.2 mg for 6 weekly injections; MAD part 2 stepped up every 2 weeks toward the higher targets (PMID 42017294). Gradual escalation is the entire amylin-class playbook for GI tolerance. No anti-nausea co-medication or dose-reduction rule appears in the abstract; one participant discontinued for GI reasons, and we know nothing about what was tried first. This is trial design, not a protocol recommendation.

Dose and Side Effects: What Was Measured, and What Wasn’t

What the trials administered: single subcutaneous doses of 0.04–2.4 mg and one 0.35 mg intravenous dose; 6 weekly doses of 0.6 or 1.2 mg; and 16 weekly doses escalated to 2.4, 4.8, or 9.0 mg (PMID 42017294). What the abstract reports against those doses: nausea in a 16.7%–33.3% band, weight loss up to 8.6%, and dose-proportional pharmacokinetics. What it does not report is which dose produced which rate — the nausea range is not attached to arms, and the 8.6% is a maximum, not a per-dose table. The safe reading: higher targets are where effect and stomach cost concentrate, and MAD part 2 — the highest-dose part — is where the nausea data came from.

DID YOU KNOW

Petrelintide was engineered to be formulated at about neutral pH — a chemistry problem the development team solved by optimizing stability while keeping potency intact (PMID 41217931). The stated reason is co-formulation: an amylin analogue that can share a vial with currently marketed weight-loss drugs. The tolerability of any such combination is, as of this writing, entirely unmeasured.

Petrelintide Alone vs Stacked: Built for Combination, Tested Alone

The molecule was explicitly designed for combination use — the development paper argues that “combinations of peptide drugs for weight management may be more effective than individual peptide drugs” and that neutral-pH stability exists “to enable coformulation with currently marketed drugs” (PMID 41217931) — yet every published human safety number comes from petrelintide alone. The stacks research forums are already sketching — petrelintide plus a GLP-1 agonist, plus retatrutide — have no published human data at all. The nearest documented analogies live on other pages: cagrilintide’s stacked profile with semaglutide, and amycretin, which fuses GLP-1 and amylin agonism into one molecule. Those are analogies, not measurements. A compound built to be stacked has only been studied unstacked.

How Petrelintide Compares to Cagrilintide, Eloralintide, and Amycretin

No head-to-head human trial exists among the amylin-class compounds, so every comparison is cross-trial — different populations, durations, cohort sizes, and reporting — and that caveat belongs in the same breath as any claim. Cagrilintide is the non-selective first-generation amylin analogue, with the largest human dataset by far. Eloralintide is Lilly’s selective amylin receptor agonist, which bet on receptor selectivity to soften the GI profile and has a full phase 2 behind it. Petrelintide is Zealand’s long-acting analogue of human amylin, which bet on chemistry and pharmacokinetics instead and has two phase 1 trials of unreported size (PMID 42017294). Amycretin is Novo Nordisk’s unimolecular GLP-1-plus-amylin agonist, which skips co-formulation by building both mechanisms into one peptide. Petrelintide’s authors claim “potential for improved GI tolerability over existing therapies,” and the placebo-matching low end of its nausea range is the evidence — phase 1 evidence, for a compound whose comparators have already been through the phase where phase 1 optimism gets tested.

Where the Trial Data Stops: The Research-Vial Reality

Everything above describes pharmaceutical-grade petrelintide, made by Zealand Pharma and dosed under supervision. A lyophilized vial from a research-chemical storefront shares a molecule name with that product and nothing else verifiable without testing — and petrelintide’s grey-market supply chain is brand new, the stage at which quality has historically been worst. The gap shows up three ways: identity and purity — a batch-matched COA is the only evidence the vial contains dose-accurate petrelintide; concentration arithmetic — reconstitution with bacteriostatic water is on the buyer, and our peptide calculator handles the math and deliberately nothing else; and no medical monitoring, the invisible ingredient in every clean phase 1 safety table. Compounds in this channel are sold strictly for non-human research use.

Sourcing and Verification

Petrelintide is about as new as a research-market compound gets — its human data was published in 2026 — and listings are appearing faster than documentation. The checklist doesn’t change: a batch-matched COA naming the compound and quantity, independent third-party testing with a verifiable report number (see our lab-testing guide), and hard skepticism toward any listing quoting the 8.6% figure as though it applied to the vial. Be doubly skeptical of any vendor calling it “the gentle amylin” — a phase 1 hypothesis dressed as a result. (Disclosure: some links on this site are affiliate links; they don’t change what we report.) Our vendor reviews show what passing documentation looks like, and our guide library covers verification in depth. We don’t yet track live petrelintide prices; when our tested vendors stock it, this section gets the live table.

US Regulatory Status

Petrelintide is an investigational compound: not FDA-approved anywhere as of this writing, described by its developers as “in clinical development as a potential treatment for weight management” (PMID 41217931). Practically, that means no prescription version exists, every vial in circulation is research-market material sold for non-human research use, and no regulator has evaluated any of those products for identity, purity, or the safety profile described above. Nor is it on any compounding list — our coverage of the FDA’s peptide compounding vote explains why that matters. When approval status changes, this section changes with it.

PERSONAL OBSERVATION — PI EDITORIAL

In the listings we’ve reviewed for compounds at this stage, the pattern is consistent: the less human data a molecule has, the more confidently the product page describes its tolerability. Petrelintide is a clean example — one paper, two small trials, no reported headcount, and vendor copy already calling it the low-nausea amylin. The placebo-floor figure is genuinely interesting. But it was produced in a cohort the authors didn’t size for us, by the company that wrote the paper, at exposures far short of those that shaped cagrilintide’s and eloralintide’s nausea columns. Until that changes, the COA is the only sentence on this page that applies to the vial in front of you.

Frequently Asked Questions

What are the most common petrelintide side effects?

Gastrointestinal events, mostly mild. In the 16-week part of the multiple-dose phase 1 trial, nausea occurred in 16.7%–33.3% of participants on petrelintide versus 16.7% on placebo. Diarrhea was rare, vomiting was reported by a single participant, and no serious or severe adverse events occurred in either trial.

How does petrelintide’s nausea rate compare with placebo?

The lowest petrelintide cohort rate, 16.7%, was identical to the placebo rate; the highest was 33.3%. The abstract reports a range without saying which dose produced which figure, and doesn’t report cohort sizes — so the gap may reflect very few people.

Did anyone stop taking petrelintide because of side effects?

One participant discontinued due to GI adverse events — the only person in the trials who experienced vomiting. The abstract doesn’t say at what dose or week.

How much weight did people lose on petrelintide in trials?

Up to 8.6% after 16 weeks of once-weekly dosing in adults with overweight or obesity. The abstract gives this as a maximum, not a per-dose average, and does not report the placebo group’s weight change.

Is petrelintide safe?

In two phase 1 trials it “appeared safe,” with no serious or severe adverse events, mostly mild GI effects, and one discontinuation — in screened, monitored participants over at most 16 weeks, in cohorts of unreported size. That is early-stage evidence, not a safety verdict, and none of it applies to research-market vials.

Can petrelintide be stacked with a GLP-1 like retatrutide or semaglutide?

Petrelintide was chemically designed for co-formulation, but no combination trial has been published. Every safety number comes from petrelintide alone; any stack’s side-effect profile is unmeasured in humans.

Glossary of Terms

  • Amylin: a pancreatic hormone co-released with insulin that signals fullness; petrelintide is a long-acting analogue of the human form.
  • ZP8396: Zealand Pharma’s development code for petrelintide.
  • Half-life: the time for drug concentration to fall by half; petrelintide’s is about 10 days, which is why it can be dosed once weekly.
  • Treatment-emergent adverse event (TEAE): any unwanted medical event beginning after dosing starts, drug-related or not; placebo groups report them too.
  • SAD / MAD: single- and multiple-ascending-dose trials — the standard phase 1 designs that test stepwise higher exposures in small cohorts.
  • Dose proportionality: blood levels rising in step with dose, making exposure predictable; petrelintide showed it at steady state.
  • COA (certificate of analysis): the lab document identifying a research vial’s contents; batch-matched or it proves nothing.

References